Chapter 220 Management of Symptomatic Osteoporotic Vertebral Compression
Vertebroplasty
Vertebral Augmentation
Kyphoplasty and vertebroplasty currently are used to treat neurologically intact patients suffering from vertebral compression fractures resulting from osteoporosis and certain neoplasms. Percutaneous vertebroplasty (PV) is an imaging-guided procedure that reinforces a compromised vertebra with polymethylmethacrylate (PMMA), alleviating pain and improving the patient’s mobility. Initially described in 1987 as a treatment for painful hemangiomas,1 the procedure now is used most widely to treat fractures and destructive lesions that cause vertebral collapse and pain. The goal of vertebral augmentation procedures is to reduce fracture pain by stabilizing the vertebral fracture, allowing patients to return to their daily living activities and exercise.
The primary indications for PV are persistently painful compression fractures, most commonly related to osteoporosis, that are unresponsive to correct medical treatment, and benign or malignant osteolytic neoplasms (e.g., hemangioma, metastasis, and myeloma). In the setting of osteoporotic fracture, PV is done primarily for pain management and secondarily to prevent further collapse.2 For neoplasm, the indications are somewhat broader, and the procedure may be done for pain management and/or stabilization. PV is not an ablative procedure, but reinforcement may reduce pain while facilitating other therapies such as radiation therapy or surgical resection and fixation and minimizing the risk of further collapse or fracture.
The specific indications for PV are as follows:
• Osteoporotic compression fractures causing pain refractory to nonsurgical therapy and interfering with normal activities of daily living
• Multiple compression deformities resulting in, or threatening to result in, respiratory or gastrointestinal compromise or loss of balance, increasing fall risk
• Unstable compression fractures showing movement or progressive collapse
• Osteolysis due to malignant or benign neoplasms with fracture or impending risk of fracture
Relative contraindications include the following:
• An asymptomatic and stable fracture
• A patient showing symptomatic improvement with time
• Prophylactic vertebral augmentation in the absence of any acute compression fracture
Other, less common, relative contraindications are (1) retropulsion of fracture fragment(s) causing substantial spinal canal compromise (e.g., a burst-type fracture); (2) neoplasm extending into the epidural space with substantial spinal canal compromise; (3) severe vertebral collapse such that it would be technically challenging to place a needle; (4) chronic stable fracture without pain; and (5) treatment of more than three levels at any one time. Acute traumatic fracture of a nonosteoporotic vertebra also is considered a contraindication.
Technical Performance of Vertebroplasty
The traditional mode for PV has been to perform bilateral injections via a transpedicular or dorsolateral (parapedicular) approach using a two-needle technique (Figs. 220-1 to 220-5). Unipedicular injections also can provide substantial vertebral reinforcement when enough cement is injected to cross the midline of the vertebral body and provide a similar distribution to bipedicular injections.3
The modalities used for imaging are either fluoroscopy or CT. PV can be accomplished with either single-plane or biplane fluoroscopy. Biplane fluoroscopy is considered ideal because one can view orthogonal projections without changing tube position, greatly reducing procedure time. CT requires repositioning the gantry between needle manipulations, imaging, and injection, consuming useful injection. CT fluoroscopy allows the user to generate real-time CT sections while performing procedures, but concerns with CT fluoroscopy revolve around the increased radiation dose delivered to personnel and the operator in the room during the procedure. For most purposes, C-arm fluoroscopy provides adequate imaging, is readily available, and is less time-consuming.
Cement Handling
The two most popular preparations used for PV are Cranioplastic Type I Slow Set (Codman, Johnson & Johnson) and Simplex P (Stryker-Howmedica-Osteonics). Simplex P is approved by the FDA as a structural device for use in pathologic fractures in bones throughout the body, but the approval does not specify PV per se. Simplex P was the original PMMA used for the first PV by Deramond in 1984 and has remained popular for this application in Europe and the United States. In a comparison of three types of PMMA in cadavers (Cranioplastic, Osteobond, and Simplex P), vertebrae were significantly stronger after cement injection, regardless of cement type. However, Simplex P restored stiffness to initial values, whereas vertebrae injected with Cranioplastic were significantly less stiff than in their initial state.4
These preparations (mixed according to the package insert) produce cement that is difficult to inject and poorly visualized by fluoroscopy (although quite suitable for radiography). Thus the addition of an opaque agent (sterile barium, tantalum, or tungsten) is required. Sterile barium preparations are available from Parallax (Mountain View, CA) or Bryan Corporation (Woburn, MA). It has been determined that PMMA mixtures containing approximately 25% to 30% by weight of barium sulfate will provide opacification sufficient for the performance of fluoroscopically guided PV.4,5
With respect to how much cement mixture to inject, an in vitro study demonstrated that initial vertebral body strength is restored with as little as 2 mL of cement, but significantly greater stiffness requires 4 to 8 mL, depending on vertebral level and type of cement.6 These data provide guidance on the cement volumes needed to restore biomechanical integrity and parallel the clinical experience that many patients do well without having the cement fill an entire vertebral body. Hence, the trend has been to use less cement, minimizing the risk of complications from extravasation.
New biomaterials such as nanoparticles and Orthocomp (a glass-ceramic-reinforced BisGMA/BisEMA/TEGDMA matrix composite) are being actively pursued, and it is likely that specific formulations will be available for PV in the near future.7
Treating Tumors
Vertebroplasty may play an important role in palliation for the patient with vertebral metastases and in improving independence and function during more definitive systemic therapy. Tumors that are particularly radiosensitive are most appropriate to PV, because local control can be obtained as easily after stabilization as before. Tumors that require resection with a surgical margin, such as primary malignancies or locally aggressive benign tumors, are not appropriate for PV. Although there is some theoretical margin of tumor-kill associated with the thermal effect of the PMMA mass,8 the application of PV in the setting of neoplasm is not intended as an ablative procedure, and the goal is to provide structural support primarily, with the secondary goal of pain relief. The amount of PMMA used may be greater in an osteolytic spinal lesion than in a compression fracture, because the trend to minimize injectant volume in osteoporosis (i.e., filling the fracture line) does not apply in an erosive or destructive lesion.
Metastases are the lesions most commonly treated by PV, but large, symptomatic hemangiomas also may require ablation and stabilization with PMMA injection. Hemangiomas have a benign histology, but may grow aggressively and cause pain through either tissue distortion or pathologic fracture. PV stabilizes the vertebral body and obliterates the vascular sinusoids that make up the mass of the hemangioma. Subsequent surgery may then be focused on decompression, if needed.9 In this fashion, PV is another adjuvant treatment akin to intralesional sclerosis or embolotherapy preoperatively. PV also is effective in treating vertebral metastases that result in pain or instability, providing immediate and long-term pain relief.10 MRI is crucial for preoperative planning to evaluate the soft tissue extent of the tumor (e.g., spinal canal involvement, neuroforaminal encroachment, and status of the posterior longitudinal ligament).
Complications
Fortunately, major complications are uncommon. The most common complication is radicular pain caused by migration of cement into the epidural venous plexus. In most patients, intradiscal and paravertebral leaks of cement have no clinical importance.11 However, there have been case reports of severe neurologic complications, underscoring the need for appropriate safeguards as outlined previously.12 Permanent paralysis has been reported, but is exceptionally uncommon if the procedure is performed in a controlled, image-guided fashion (by using a biplane real-time fluoroscopy suite). Rib, pedicle, or transverse process fractures also have been noted. One case has been reported of a pulmonary embolism caused by acrylic cement. This rare complication was believed to have occurred because perivertebral venous migration was not recognized.13 The anticipated complication rate is higher when treating neoplasms (10%) than for osteoporotic compression fractures (1% to 3%).
Outcomes
Taylor et al. performed a systematic review and meta-regression to compare the efficacy and safety of balloon kyphoplasty and vertebroplasty for the treatment of vertebral compression fractures, and to examine the prognostic factors that predict outcome. They found level III evidence to support balloon kyphoplasty and vertebroplasty as effective therapies in the management of patients with symptomatic osteoporotic vertebral compression fractures refractory to conventional medical therapy. Although there was a good ratio of benefit to harm for both procedures, balloon kyphoplasty appeared to offer the better adverse event profile.14